Three things to know:
1. The study will enroll 320 people aged 30 to 70 years old who have been diagnosed with leg pain from a herniated lumbar disc.
2. A Phase 3 study in Japan demonstrated that an injection of the drug into the nucleus pulposus reduced nerve root by decreasing pressure and volume of herniation, resulting in less pain.
3. SI-6603, the study drug, has yet to be approved for use in the U.S. by the FDA.
More articles on spine:
Zimmer Biomet replaces retiring CFO
Stryker expands overseas & more: 6 device company key notes
Pacira appoints former Johnson & Johnson exec Max Reinhardt president
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
